← Back to Screener
Evommune, Inc. (EVMN)
Price$22.17
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)8.23%
Price vs S&P 500 (4W)-10.16%
VGM Score65.16
Market Capitalization$836.71M
All Metrics
Book Value / Share (Quarterly)$8.46
Price vs S&P 500 (YTD)24.76%
Net Profit Margin (TTM)-606.20%
EPS (TTM)$-3.87
10-Day Avg Trading Volume0.44M
EPS Excl Extra (TTM)$-3.87
EPS (Annual)$-2.29
ROI (Annual)-33.42%
Cash / Share (Quarterly)$5.87
Revenue Growth QoQ (YoY)85.71%
ROA (Last FY)-30.62%
EBITD / Share (TTM)$-4.52
Operating Margin (TTM)-744.36%
Cash Flow / Share (Annual)$-2.55
P/B Ratio2.75x
P/B Ratio (Quarterly)2.72x
Net Income / Employee (Annual)$-1,434,800
EPS Incl Extra (Annual)$-2.29
Current Ratio (Annual)8.57x
Quick Ratio (Quarterly)19.94x
3-Month Avg Trading Volume0.54M
Revenue / Employee (TTM)$333,300
P/S Ratio (Annual)64.36x
Asset Turnover (Annual)0.06x
52-Week High$33.20
EPS Excl Extra (Annual)$-2.29
26-Week Price Return24.16%
Quick Ratio (Annual)8.33x
13-Week Price Return-12.77%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)20.36x
Enterprise Value$789.48M
Revenue / Employee (Annual)$270,800
Pretax Margin (Annual)-529.77%
Cash / Share (Annual)$4.96
3-Month Return Std Dev72.45%
Net Income / Employee (TTM)$-2,472,200
ROE (Last FY)-33.50%
EPS Basic Excl Extra (Annual)$-2.29
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.87
P/S Ratio (TTM)52.29x
Revenue / Share (Annual)$0.43
Year-to-Date Return35.69%
5-Day Price Return1.57%
EPS Normalized (Annual)$-2.29
Net Profit Margin (Annual)-529.77%
Month-to-Date Return-2.40%
EBITD / Share (Annual)$-2.65
Operating Margin (Annual)-623.62%
EPS Basic Excl Extra (TTM)$-3.87
P/B Ratio (Annual)2.63x
Pretax Margin (TTM)-606.20%
Book Value / Share (Annual)$6.83
Price vs S&P 500 (13W)-22.51%
Beta0.08x
Revenue / Share (TTM)$0.48
52-Week Low$13.88
gGradeA
mGradeC
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.64est. -0.76
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.36
4.36
4.33
4.31
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
EVMNEvommune, Inc. | — | A | C | $22.17 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Evommune Inc is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, including chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's pipeline features two lead candidates, EVO756 and EVO301, currently in clinical development.